Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yilei Mao is active.

Publication


Featured researches published by Yilei Mao.


The Lancet | 2012

A pilot programme of organ donation after cardiac death in China

Jiefu Huang; J. Michael Millis; Yilei Mao; M. Andrew Millis; Xinting Sang; Shouxian Zhong

Chinas aims are to develop an ethical and sustainable organ transplantation system for the Chinese people and to be accepted as a responsible member of the international transplantation community. In 2007, China implemented the Regulation on Human Organ Transplantation, which was the first step towards the establishment of a voluntary organ donation system. Although progress has been made, several ethical and legal issues associated with transplantation in China remain, including the use of organs from executed prisoners, organ scarcity, the illegal organ trade, and transplantation tourism. In this Health Policy article we outline the standards used to define cardiac death in China and a legal and procedural framework for an organ donation system based on voluntary donation after cardiac death that adheres to both Chinas social and cultural principles and international transplantation standards.


Journal of Surgical Oncology | 2009

A prospective clinical study on early recurrence of hepatocellular carcinoma after hepatectomy

Xin Lu; Haitao Zhao; Huayu Yang; Yilei Mao; Xinting Sang; Ruoyu Miao; Yiyao Xu; Shunda Du; Haifeng Xu; Tianyi Chi; Zhiying Yang; Shouxian Zhong; Jiefu Huang

To determine more precisely time interval from resection to recurrence of hepatocellular carcinoma (HCC) and to identify the risk factors associated with postoperative recurrence.


Journal of Surgical Oncology | 2012

Primary liver cancer presenting as pyogenic liver abscess: Characteristics, diagnosis, and management†‡

Cong Li; Guangbing Li; Ruoyu Miao; Xin Lu; Shouxian Zhong; Xinting Sang; Yilei Mao; Haitao Zhao

Primary liver cancer (PLC) presenting as pyogenic liver abscess (PLA) is potentially life‐threatening, but has been occasionally reported, especially for cholangiocarcinoma.


Liver Transplantation | 2015

Voluntary organ donation system adapted to Chinese cultural values and social reality.

Jiefu Huang; J. Michael Millis; Yilei Mao; M. Andrew Millis; Xinting Sang; Shouxian Zhong

Organ donation and transplant systems have unique characteristics based on the local culture and socioeconomic context. Chinas transplant and organ donation systems developed without regulatory oversight until 2006 when regulation and policy were developed and then implemented over the next several years. Most recently, the pilot project of establishing a voluntary citizen‐based deceased donor program was established. The pilot program addressed the legal, financial, and cultural barriers to organ donation in China. The pilot program has evolved into a national program. Significantly, it established a uniquely Chinese donor classification system. The Chinese donor classification system recognizes donation after brain death (category I), donation after circulatory death (category II), and donation after brain death followed by circulatory death (category III). Through August 2014, the system has identified 2326 donors and provided 6416 organs that have been allocated though a transparent organ allocation system. The estimated number of donors in 2014 is 1147. As Chinas attitudes toward organ donation have matured and evolved and as China, as a nation, is taking its place on the world stage, it is recognizing that its past practice of using organs from executed prisoners is not sustainable. It is time to recognize that the efforts to regulate transplantation and provide voluntary citizen‐based deceased organ donation have been successful and that China should use this system to provide organs for all transplants in every province and hospital in China. At the national organ transplant congress on October 30, 2014, the Chairman of the Chinas national organ donation and transplantation committee, Jeifu Huang required all hospitals to stop using organs from executed prisoners immediately and the civilian organ donation will be sole source for organ transplant in China starting January 2015. Liver Transpl 21:419–422, 2015.


Gastroenterology | 2015

mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice

Xinxin Chen; Yanan Wang; Jun Tao; Yuzhuo Shi; Xiaochen Gai; Fuqiang Huang; Qian Ma; Zhenzhen Zhou; Hongyu Chen; Haihong Zhang; Zhibo Liu; Qian Sun; Haiyong Peng; Rongrong Chen; Yanling Jing; Huayu Yang; Yilei Mao; Hongbing Zhang

BACKGROUND & AIMS Levels of the Golgi protein 73 (GP73) increase during development of hepatocellular carcinoma (HCC); GP73 is a serum marker for HCC. However, little is known about the mechanisms or effects of GP73 during hepatic carcinogenesis. METHODS GP73 was overexpressed from a retroviral vector in HepG2 cells, which were analyzed in proliferation and migration assays. Xenograft tumors were grown from these cells in nude mice. The effects of monoclonal antibodies against GP73 were studied in mice and cell lines. GP73(-/-), GP73(+/-), and GP73(+/+) mice were given injections of diethylnitrosamine to induce liver injury. Levels of GP73 were reduced in MHCC97H, HCCLM3, and HepG2.215 cell lines using small hairpin RNAs; xenograft tumors were grown in mice from MHCC97H-small hairpin GP73 or MHCC97H-vector cells. We used microarray analysis to compare expression patterns between GP73-knockdown and control MHCC97H cells. We studied the effects of the mechanistic target of rapamycin (mTOR) inhibitor rapamycin on GP73 expression in different cancer cell lines and on growth of tumors in mice. Levels of GP73 and activated mTOR were quantified in human HCC tissues. RESULTS Xenograft tumors grown from HepG2 cells that expressed GP73 formed more rapidly and more metastases than control HepG2 cells in mice. A monoclonal antibody against GP73 reduced proliferation of HepG2 cells and growth of xenograft tumors in mice. GP73(-/-) mice had less liver damage after administration of diethylnitrosamine than GP73(+/-) or GP73(+/+) mice. In phosphatase and tensin homolog-null mouse embryonic fibroblasts with constitutively activated mTOR, GP73 was up-regulated compared with control mouse embryonic fibroblasts; this increase was reversed after incubation with rapamycin. Expression of GP73 also was reduced in HCC and other cancer cell lines incubated with rapamycin. mTORC1 appeared to regulate expression of GP73 in cell lines. Activated mTOR correlated with the level of GP73 in human HCC tissues. Injection of rapamycin slowed the growth of xenograft tumors from MHCC97H-vector cells, compared with MHCC97H-short hairpin GP73 cells. CONCLUSIONS Increased expression of GP73 promotes proliferation and migration of HCC cell lines and growth of xenograft tumors in mice. mTORC1 regulates the expression of GP73, so GP73 up-regulation can be blocked with rapamycin. mTOR inhibitors or other reagents that reduce the level or activity of GP73 might be developed for the treatment of HCC.


Cases Journal | 2008

Severe adult ileosigmoid intussusception prolapsing from the rectum: A case report

Rongrong Chen; Haitao Zhao; Xinting Sang; Yilei Mao; Xin Lu; Yifan Yang

Intussusception is a pediatric condition that rarely presents in adults. In this article, we report a case of a 36 year-old man initially presenting with abdominal pain and rectal prolapse, however, surgical reduction of the rectal prolapse did no relief his symptoms. Physical examination, abdominal plain film, barium enema and colonoscopy confirmed the presence of a large intra-abdominal mass, but the origin of the mass was revealed only upon laparotomy. During the surgery, it was noted that the ileum and the sigmoid colon was connected by a 15 cm × 12cm mass, covered by an extremely dilated intestinal tissue. The resected tissue pathology demonstrated a 9 cm × 6 cm × 5 cm submucosal lipoma at the ileocecal junction without evidence of malignancy. The patients post-surgical course was uneventful. Diagnostic and therapeutic problems related to adult intussusception are reviewed.


American Journal of Surgery | 2011

The effects of urinary trypsin inhibitor on liver function and inflammatory factors in patients undergoing hepatectomy: a prospective, randomized, controlled clinical study

Huayu Yang; Yilei Mao; Xin Lu; Xinting Sang; Shunda Du; Haitao Zhao; Yiyao Xu; Haifeng Xu; Zhiying Yang; Tianyi Chi; Shouxian Zhong; Jiefu Huang

BACKGROUND The inhibition of inflammation exerts benefits following massive hepatectomy in animals but not in the clinic. The aim of this study was to investigate the effectiveness and mechanism of ulinastatin on liver function and outcomes following hepatectomy. METHODS One hundred seventy-six patients undergoing hepatectomy were randomized into the treatment group (n = 86) and the control group (n = 90), receiving ulinastatin 150,000 U twice daily for 3 days and saline vehicle, respectively. Liver function, coagulation, thrombokinase, lymphocyte subsets CD4 and CD8, C-reactive protein, inducible nitric oxide synthase, and cytokines were measured. Clinical outcomes were also evaluated. RESULTS Serum alanine transaminase, aspartate transferase, inducible nitric oxide synthase, and tumor necrosis factor-α levels were significantly lower after ulinastatin treatment, and the response of bilirubin was delayed. The benefits of ulinastatin were shown mainly in major hepatectomy earlier after surgery. The treatment significantly reduced hospital length of stay and recovery-related cost. CONCLUSIONS Ulinastatin protects liver function and improves clinical outcomes, possibly via the inhibition of inflammation and oxidation at an earlier stage following major hepatectomy.


Nucleic Acids Research | 2015

Dr.VIS v2.0: an updated database of human disease-related viral integration sites in the era of high-throughput deep sequencing.

Xiaobo Yang; Ming Li; Qi Liu; Yabing Zhang; Junyan Qian; Xueshuai Wan; Anqiang Wang; Haohai Zhang; Chengpei Zhu; Xin Lu; Yilei Mao; Xinting Sang; Haitao Zhao; Yi Zhao; Xiaoyan Zhang

Dr.VIS is a database of human disease-related viral integration sites (VIS). The number of VIS has grown rapidly since Dr.VIS was first released in 2011, and there is growing recognition of the important role that viral integration plays in the development of malignancies. The updated database version, Dr.VIS v2.0 (http://www.bioinfo.org/drvis or bminfor.tongji.edu.cn/drvis_v2), represents 25 diseases, covers 3340 integration sites of eight oncogenic viruses in human chromosomes and provides more accurate information about VIS from high-throughput deep sequencing results obtained mainly after 2012. Data of VISes for three newly identified oncogenic viruses for 14 related diseases have been added to this 2015 update, which has a 5-fold increase of VISes compared to Dr.VIS v1.0. Dr.VIS v2.0 has 2244 precise integration sites, 867 integration regions and 551 junction sequences. A total of 2295 integration sites are located near 1730 involved genes. Of the VISes, 1153 are detected in the exons or introns of genes, with 294 located up to 5 kb and a further 112 located up to 10 kb away. As viral integration may alter chromosome stability and gene expression levels, characterizing VISes will contribute toward the discovery of novel oncogenes, tumor suppressor genes and tumor-associated pathways.


Hepatobiliary surgery and nutrition | 2013

Peripheral primitive neuroectodermal tumors arising in the pancreas: the first case report in Asia and a review of the 14 total reported cases in the world.

Yilei Mao; Xinting Sang; Naixin Liang; Huayu Yang; Xin Lu; Zhiying Yang; Shunda Du; Yiyao Xu; Haitao Zhao; Shouxian Zhong; Jiefu Huang; J. Michael Millis

OBJECTIVE To discuss the diagnosis and treatment of peripheral primitive neuroectodermal tumors of the pancreas based on our case and all the cases in the world. METHODS The first case of peripheral primitive neuroectodermal tumors of the pancreas in Asia was preliminarily reported by our group in 2006. The patient underwent three operations for the primary tumor and recurrences over 41 months prior to the patients death in November 2007. All 14 reported cases of pancreatic PNETs in the world were analyzed. The corresponding literatures on its diagnosis and treatment of were reviewed. RESULTS A 13 year-old female patient was diagnosed with pancreatic PNETs by the clinical, microscopic, immunohistochemical features, and cytogenetic analysis after the resection of the tumor located in the uncinate process of the pancreas at PUMC Hospital. During the follow-up course, radiotherapy and chemotherapy were given after the first operation. Two additional operations were performed 10 months and 25 months after the first one, respectively, because of tumor recurrence. The patient died 41 months after the initial diagnosis with the recurrence and metastasis that were not suitable for a further surgery. Primitive neuroectodermal tumors of the pancreas are extremely rare. A review of the worlds literature on this tumor identified fourteen cases with a mean survival time of 12 months (ranging from 6 to 50 months). These patients often have no specific clinical symptoms, but most do present with abdominal pain and/or jaundice. The diagnosis is established by small round tumor cells seen on light microscopy, immunohistochemical features of positive P30/32(MIC2) with at least two positive neuronal markers., and cytogenetic analysis showing characteristic translocation of t[11;22][q24;q12]. Since pancreatic PNETs are highly aggressive, early diagnosis, immediate surgical resection and re-resection if possible, early radiotherapy and chemotherapy and close follow-up are required. CONCLUSIONS Peripheral primitive neuroectodermal tumors can arise in pancreas. The diagnosis and treatment should be made as early as possible, aggressive surgeries for the primary and recurrences may help to improve the prognosis.


Cancer biology and medicine | 2016

Three-dimensional printing: review of application in medicine and hepatic surgery

Rui Yao; Gang Xu; Shuangshuang Mao; Huayu Yang; Xinting Sang; Wei Sun; Yilei Mao

Three-dimensional (3D) printing (3DP) is a rapid prototyping technology that has gained increasing recognition in many different fields. Inherent accuracy and low-cost property enable applicability of 3DP in many areas, such as manufacturing, aerospace, medical, and industrial design. Recently, 3DP has gained considerable attention in the medical field. The image data can be quickly turned into physical objects by using 3DP technology. These objects are being used across a variety of surgical specialties. The shortage of cadaver specimens is a major problem in medical education. However, this concern has been solved with the emergence of 3DP model. Custom-made items can be produced by using 3DP technology. This innovation allows 3DP use in preoperative planning and surgical training. Learning is difficult among medical students because of the complex anatomical structures of the liver. Thus, 3D visualization is a useful tool in anatomy teaching and hepatic surgical training. However, conventional models do not capture haptic qualities. 3DP can produce highly accurate and complex physical models. Many types of human or animal differentiated cells can be printed successfully with the development of 3D bio-printing technology. This progress represents a valuable breakthrough that exhibits many potential uses, such as research on drug metabolism or liver disease mechanism. This technology can also be used to solve shortage of organs for transplant in the future.

Collaboration


Dive into the Yilei Mao's collaboration.

Top Co-Authors

Avatar

Xinting Sang

Peking Union Medical College Hospital

View shared research outputs
Top Co-Authors

Avatar

Xin Lu

Peking Union Medical College Hospital

View shared research outputs
Top Co-Authors

Avatar

Huayu Yang

Peking Union Medical College Hospital

View shared research outputs
Top Co-Authors

Avatar

Haifeng Xu

Peking Union Medical College Hospital

View shared research outputs
Top Co-Authors

Avatar

Shouxian Zhong

Peking Union Medical College Hospital

View shared research outputs
Top Co-Authors

Avatar

Haitao Zhao

Peking Union Medical College Hospital

View shared research outputs
Top Co-Authors

Avatar

Jiefu Huang

Peking Union Medical College Hospital

View shared research outputs
Top Co-Authors

Avatar

Wenjun Liao

Peking Union Medical College Hospital

View shared research outputs
Top Co-Authors

Avatar

Lejia Sun

Peking Union Medical College Hospital

View shared research outputs
Top Co-Authors

Avatar

Yiyao Xu

Peking Union Medical College Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge